Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
77.56 USD | +0.77% | -4.28% | -19.56% |
Financials (USD)
Sales 2024 * | 2.74B | Sales 2025 * | 3.09B | Capitalization | 14.73B |
---|---|---|---|---|---|
Net income 2024 * | 363M | Net income 2025 * | 504M | EV / Sales 2024 * | 5.12 x |
Net cash position 2024 * | 698M | Net cash position 2025 * | 1.34B | EV / Sales 2025 * | 4.33 x |
P/E ratio 2024 * |
42.3
x | P/E ratio 2025 * |
30
x | Employees | 3,401 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
Latest transcript on BioMarin Pharmaceutical Inc.
1 day | +0.77% | ||
1 week | -4.28% | ||
Current month | -3.96% | ||
1 month | -13.89% | ||
3 months | -12.63% | ||
6 months | -11.38% | ||
Current year | -19.56% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
Director/Board Member | 70 | 05-05-15 | |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.45% | 1 M€ | +0.15% | - | |
1.79% | 0 M€ | 0.00% | - | |
1.59% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 77.56 | +0.77% | 3,433,447 |
24-05-16 | 76.97 | -4.27% | 3,858,058 |
24-05-15 | 80.4 | +0.94% | 2,124,282 |
24-05-14 | 79.65 | -1.06% | 1,530,829 |
24-05-13 | 80.5 | -0.65% | 1,291,756 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.56% | 14.73B | |
-2.32% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
+58.05% | 25.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B | |
-6.32% | 8.35B |
- Stock Market
- Equities
- BMRN Stock